Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $141.11M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.31M
Average 0.28M
STRO EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Sutro Biopharma, Inc.NASDAQ: STRO
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$294.17, compared with -$9.1 a year earlier. Trailing-twelve-month EPS (Basic) was -$307.72.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$8.12 (+63.9%) for the fiscal year ending Dec 2026, a step up from the +24.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$294.17-5297.6% QoQ
- Last fiscal yearDec 2025
- -$22.49+24.0% YoY
- LTMMar 2026
- -$307.72-936.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -3132.6% | -56.7% | +3075.9 pp |
| 1 year | +24.0% | +63.9% | +39.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (22.49) USD
- Year-over-year change
- +24.0%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.49) | +24.0% |
| FY2024 | 2024-12-31 | (29.60) | -66.3% |
| FY2023 | 2023-12-31 | (17.80) | +24.3% |
| FY2022 | 2022-12-31 | (23.50) | -2.6% |
| FY2021 | 2021-12-31 | (22.90) | — |
EPS (Basic) vs competitors
How STRO compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -936.1% is the lowest of 9, against a peer median of +12.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -€0.61 EUR | +18.5% | — | |
| LTM Mar 2026 | -$0.63 USD | +54.7% | — | |
| FY2025 | -$1 USD | -257.1% | — | |
| LTM Mar 2026 | -$1.74 USD | +5.4% | — | |
| LTM Mar 2026 | -$1.84 USD | +49.0% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | -$2.15 USD | +85.6% | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$3.55 USD | -11.3% | — |
| LTM Mar 2026 | -$4.35 USD | -84.3% | — | |
| LTM Mar 2026 | -$307.72 USD | -936.1% | — | |
| Peer median (excluding STRO) | — | +12.0% | — | |
Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.88M | 67.77M | 153.73M | 62.04M | 102.48M |
| Cost of Revenue | 9.77M | 8.29M | 6.82M | 7.22M | 7.32M |
| Gross Profit | 52.11M | 59.48M | 146.92M | 54.83M | 95.16M |
| Gross Margin | 84.2% | 87.8% | 95.6% | 88.4% | 92.9% |
| Research & Development | 104.4M | 137.17M | 180.43M | 252.04M | 166.42M |
| Selling, General & Admin | 56M | 59.54M | 62.58M | 48.45M | 41.02M |
| Operating Expenses | 150.63M | 188.43M | 236.19M | 293.28M | 200.11M |
| Depreciation & Amortization | 4.84M | 8.29M | 6.82M | 7.22M | 7.32M |
| EBITDA | (97.56M) | (105.07M) | (67.92M) | (180.45M) | (145.65M) |
| EBITDA Margin | -157.7% | -155.0% | -44.2% | -290.9% | -142.1% |
| Operating Income | (98.52M) | (128.94M) | (89.28M) | (238.45M) | (104.95M) |
| Operating Margin | -159.2% | -190.3% | -58.1% | -384.3% | -102.4% |
| Interest Income | 577K | 3.46M | 14.51M | 44.43M | 9.25M |
| Interest Expense | 3.14M | 3.35M | 23.75M | 31.07M | 38.21M |
| Other Income / Expenses | (7.01M) | 12.24M | 677K | 13.36M | (86.23M) |
| Income Before Tax | (105.54M) | (116.7M) | (88.6M) | (225.1M) | (191.18M) |
| Pre-Tax Margin | -170.6% | -172.2% | -57.6% | -362.8% | -186.5% |
| Income Tax Expense | 0 | 2.5M | 18.19M | 2.36M | (93K) |
| Net Income | (105.54M) | (119.2M) | (106.79M) | (227.46M) | (191.09M) |
| Net Margin | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
| EPS (Basic) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| EPS (Diluted) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| Weighted Avg Shares | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
| Weighted Avg Shares (Diluted) | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
Sutro Biopharma, Inc.
NASDAQ:STRO
Intrinsic Alpha fair value
Locked
Current Price
$8.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.